Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 9/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20234858 | 0.83 | EBP (0.50) | EBPSIGMAR1GRIN1GRIN2BESR1 | |
| SCHEMBL25342316 | 0.80 | ESR1 (0.45) | EBPSIGMAR1ESR1MAOAMAOB | |
| SCHEMBL737426 | 0.79 | GRIN1 (0.47) | GRIN1GRIN2BHRH3 | |
| SCHEMBL20211928 | 0.79 | EBP (0.49) | EBPSIGMAR1GRIN1GRIN2BESR1 | |
| SCHEMBL29632097 | 0.79 | EBP (0.49) | EBPSIGMAR1GRIN1GRIN2BESR1 | |
| SCHEMBL18815872 | 0.78 | ESR1 (0.69) | EBPSIGMAR1ESR1MAOAMAOB | |
| SCHEMBL20211866 | 0.78 | EBP (0.47) | EBPSIGMAR1GRIN1GRIN2BESR1 | |
| SCHEMBL18871744 | 0.77 | ESR1 (0.58) | EBPSIGMAR1ESR1MAOAMAOB | |
| SCHEMBL20234951 | 0.77 | ESR1 (0.57) | EBPSIGMAR1ESR1MAOAMAOB | |
| SCHEMBL20214249 | 0.75 | ESR1 (0.53) | EBPSIGMAR1ESR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | EBP 80/4885SIGMAR1 42/4885GRIN1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.